Evidence map›Paper›PMID 25117809›Full record

GuidelineBritish journal of cancer2014

Guidelines for the use of cell lines in biomedical research.

R J Geraghty, A Capes-Davis, J M Davis, J Downward, R I Freshney, I Knezevic, R Lovell-Badge, J R W Masters, J Meredith, G N Stacey and 3 more

Abstract readGuideline
In one paragraph

Guideline in British journal of cancer, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 222 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
222citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

222 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

162 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors.

R J GeraghtyCancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Robinson Way, Cambridge CB2 0RE, UK.
A Capes-DavisCellBank Australia, Children's Medical Research Institute, Locked Bag 23, Wentworthville, New South Wales 2145, Australia.
J M DavisSchool of Life and Medical Sciences, University of Hertfordshire, College Lane, Hatfield, Hertfordshire AL10 9AB, UK.
J DownwardCancer Research UK, London Research Institute, 44 Lincoln's Inn Fields, London WC2A 3LY, UK.
R I FreshneyInstitute for Cancer Sciences, University of Glasgow, 24 Greenwood Drive, Bearsden, Glasgow G61 2HA, UK.
I KnezevicDepartment of Essential Medicines and Health Products, Quality, Safety and Standards Team, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland.
R Lovell-BadgeMRC National Institute for Medical Research, The Ridgeway, Mill Hill, London NW7 1AA, UK.
J R W MastersUniversity College London, 67 Riding House Street, London W1W 7EJ, UK.
J MeredithCancer Research UK, Angel Building, 407 St John Street, London EC1V 4AD, UK.
G N StaceyNational Institute for Biological Standards and Control, A Centre of the Medicines and Healthcare Products Regulatory Agency, Blanche Lane, South Mimms, Herts EN6 3QG, UK.
P ThravesCulture Collections, Public Health England, Porton Down, Salisbury SP4 0JG, UK.
M ViasCancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Robinson Way, Cambridge CB2 0RE, UK.
Cancer Research UK

Funding

Cancer Research UK 15680Medical Research Council MR/L01324X/1World Health Organization 001
6 · The paper itself

Abstract

Cell-line misidentification and contamination with microorganisms, such as mycoplasma, together with instability, both genetic and phenotypic, are among the problems that continue to affect cell culture. Many of these problems are avoidable with the necessary foresight, and these Guidelines have been prepared to provide those new to the field and others engaged in teaching and instruction with the information necessary to increase their awareness of the problems and to enable them to deal with them effectively. The Guidelines cover areas such as development, acquisition, authentication, cryopreservation, transfer of cell lines between laboratories, microbial contamination, characterisation, instability and misidentification. Advice is also given on complying with current legal and ethical requirements when deriving cell lines from human and animal tissues, the selection and maintenance of equipment and how to deal with problems that may arise.

Indexed as

MycoplasmaAnimalsBiomedical ResearchCell LineCryopreservationCulture MediaEquipment and SuppliesEquipment ContaminationGenomic InstabilityHumansPhenotypeQuality ControlSafetySpecimen HandlingUnited KingdomCulture Media

Identifiers

PMID25117809
PMCPMC4453835

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.